{"entity":{"id":"nct06105021","kind":"trial","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of AFNT-211 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by Affini-T Therapeutics, Inc., active and no longer recruiting.","summary":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT06105021 by Affini-T Therapeutics, Inc., with 100 participants enrolled, started 2024-03-06 and due to reach its primary completion in 2025-12. Interventions recorded: AFNT-211.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06105021","url":"https://clinicaltrials.gov/study/NCT06105021"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["affini-t-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06105021","phase":"1/2","setting":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","sponsor":"Affini-T Therapeutics, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct06105021/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/"}]}}